Global, Regional and National Burden of Bladder Cancer, 1990 to 2016: Results from the GBD Study 2016.


Journal

The Journal of urology
ISSN: 1527-3792
Titre abrégé: J Urol
Pays: United States
ID NLM: 0376374

Informations de publication

Date de publication:
05 2019
Historique:
pubmed: 25 1 2019
medline: 30 5 2019
entrez: 25 1 2019
Statut: ppublish

Résumé

Bladder cancer is among the leading causes of cancer death worldwide. Data on the bladder cancer burden are valuable for policy-making. We aimed to estimate the burden of bladder cancer by country, age group, gender and sociodemographic status between 1990 and 2016. Data from vital registration systems and cancer registries were the input to estimate the bladder cancer burden. Mortality was estimated in an ensemble model approach, incidence was estimated by dividing mortality by the mortality-to-incidence ratio and prevalence was estimated using the mortality-to-incidence ratio as a surrogate for survival. We modeled the years lived with disability using disability weights of bladder cancer sequelae. Years of life lost were calculated by multiplying the number of deaths by age by the standard life expectancy at that age. Disability adjusted life-years were calculated by summing the years lived with disability and the years of life lost. Moreover, we also estimated the burden attributable to bladder cancer risk factors, smoking and high fasting plasma glucose using the comparative risk assessment framework of the Global Burden of Disease study. In 2016 there were 437,442 incident cases (95% UI 426,709-447,912) of bladder cancer with an age standardized incidence rate of 6.69/100,000 (95% UI 6.52-6.85). Bladder cancer led to 186,199 deaths (95% UI 180,453-191,686) in 2016 with an age standardized rate of 2.94/100,000 (95% UI 2.85-3.03). Bladder cancer was responsible for 3,315,186 disability adjusted life-years (95% UI 3,193,248-3,425,530) in 2016 with an age standardized rate of 49.45/100,000 (95% UI 47.68-51.11). Of bladder cancer deaths 26.84% (95% UI 19.78-33.91) and 7.29% (95% UI 1.49-16.19) were due to smoking and high fasting glucose, respectively, in 2016. Although the number of bladder cancer incident cases is growing globally, the age standardized incidence and number of deaths are decreasing, as mirrored by a decreasing smoking contribution.

Identifiants

pubmed: 30676477
doi: 10.1097/JU.0000000000000025
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

893-901

Commentaires et corrections

Type : CommentIn

Auteurs

Hedyeh Ebrahimi (H)

Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences , Tehran , Iran.

Erfan Amini (E)

Uro-Oncology Research Center, Tehran University of Medical Sciences , Tehran , Iran.

Farhad Pishgar (F)

Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences , Tehran , Iran.
Uro-Oncology Research Center, Tehran University of Medical Sciences , Tehran , Iran.

Sahar Saeedi Moghaddam (SS)

Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences , Tehran , Iran.
Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences , Tehran , Iran.

Behnam Nabavizadeh (B)

Uro-Oncology Research Center, Tehran University of Medical Sciences , Tehran , Iran.

Yasna Rostamabadi (Y)

Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences , Tehran , Iran.
Students' Scientific Research Center, Tehran University of Medical Sciences , Tehran , Iran.

Arya Aminorroaya (A)

Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences , Tehran , Iran.
Students' Scientific Research Center, Tehran University of Medical Sciences , Tehran , Iran.

Christina Fitzmaurice (C)

Institute for Health Metrics and Evaluation and Department of Medicine, Division of Hematology, University of Washington , Seattle , Washington.

Farshad Farzadfar (F)

Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences , Tehran , Iran.

Mohammad Reza Nowroozi (MR)

Uro-Oncology Research Center, Tehran University of Medical Sciences , Tehran , Iran.

Peter C Black (PC)

Department of Urologic Sciences, University of British Columbia , Vancouver , British Columbia , Canada.

Siamak Daneshmand (S)

Norris Comprehensive Cancer Center, University of Southern California Institute of Urology , Los Angeles , California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH